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s u m m a r y
Micronutrient status is increasingly recognized to play an important role in the health and well-being of
pregnant women and in the development and long-term health of the offspring. On 26th e 28th
February 2009, The Child Health Foundation invited leading experts in this area to a scientiﬁc workshop
at Obergurgl, Austria to review and critically discuss current knowledge, to identify issues that may need
to be addressed in future recommendations, and to highlight priorities and opportunities for future
research. This report summarizes updated key conclusions of the workshop with regards to micro-
nutrients’ intake and physiological role related to mother, placenta and fetus, as well as relevance for
adverse pregnancy and long-term outcomes.
 2011 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
1. Introduction
A balanced diet with adequate energy intake usually provides an
adequate supply of the essential micronutrients. Although
a balanced diet is generally accessible for the European population,
speciﬁc groups have inadequate vitamin and mineral intakes,
especially with regards to iron, iodide, folic acid, vitamin D and
vitamin B12.1 Micronutrient malnutrition represents an important
challenge for public health worldwide, particularly in vulnerable
population groups such as pregnant women. For example, a study
in Hackney, London, showed that 78% mothers had an inadequate
diet, meeting fewer than four of sixteen dietary reference intake
values.2 Upon follow-up at 9 months post-partum, over half of the
un-supplemented, inadequate-diet group remained severely deﬁ-
cient in folate and had low serum ferritin levels. The adequacy of
micronutrient intake during pregnancy is related to environmental,
cultural and demographic variables, such as maternal age, clothing,
geography or socioeconomic status (SES). Studies of plasma
biomarkers suggest that SES signiﬁcantly affects vitamin intakes. In
the European Prospective Investigation of Cancer Norfolk study,
individuals in manual social classes, or those who lived in the most
deprived areas had signiﬁcantly lower levels of plasma ascorbic
acid compared to those in non-manual social classes, or who lived
in less deprived areas.3 Similarly, in a study conducted in the United
Kingdom, plasma concentrations of vitamins C and B12, riboﬂavin,
and beta-carotene were lower in the low-SES group than in the
high-SES group.4 The French EVA study showed a positive associ-
ation between SES participants and their selenium and carotenoid
status.5 Low income pregnant or breastfeeding women are at
greater risk of insufﬁcient vitamin and mineral intakes, inducing
iron and vitamin A deﬁciencies.5 Indeed, risk for pregnancy related
diseases, malformations, preterm birth or low-birthweight (LBW)
increases with socioeconomic deprivation and may therefore, at
least in part, be related to poor micronutrient status.5
2. The physiological role of micronutrients in pregnancy
During the childbearing period, many women have inadequate
dietary intake of several water soluble vitamins, especially folate.
Micronutrient deﬁciencies or suboptimal/inadequate intakes may
be associated with signiﬁcantly elevated reproductive risks,
ranging from infertility to fetal structural defects and long-term
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diseases.6,7 Similarly, there is evidence demonstrating a role for
micronutrient supplementation reducing the risk of some preg-
nancy disorders.8,9 Micronutrients may affect pregnancy outcomes
through alterations in maternal and fetal metabolism owing to
their role/involvement in enzymes activity, signal transduction and
transcription pathways, biological functions and oxidative stress,
but the biological mechanisms underpinning these associations are
not completely understood.10
2.1. Folic acid and vitamin B12
Folate and folic acid serve as the precursors for the coenzyme
tetrahydrofolate in single-carbon transfer in the metabolism of
amino acids and nucleic acids as well as substrate donors in the re-
methylation of homocysteine into methionine, catalyzed by
methionine synthase and 5,10-methylenetetrahydrofolate reduc-
tase (MTHFR). An inadequate dietary folate intake results in
a reduction of DNA biosynthesis and thereby of cell division,
leading to anemia, leucopenia, thrombocytopenia and other
adverse effects.11
An overview of one-carbon metabolism is shown in Fig. 1. The
predominant folate transport and storage form within the body is
5-methyltetrahydrofolate (5-MTHF). Synthetic folic acid is
a precursor to the effective vitamin form. Folic acid is partly
transformed in the mucosa cell to dihydrofolate (DHF) and tetra-
hydrofolate (THF) and later in the liver to 10-formyl-THF and 5,10-
methylene-THF. MTHFR catalyzes the transformation of 5,10-
methylene-THF into 5-MTHF.13 A decrease in the methylation
cycle is expressed in elevation of plasma total homocysteine (tHcy),
or hyperhomocysteinemia (HHCY). HHCY can be inherited, i.e.
genetic polymorphisms of MTHFR or acquired, i.e. folate and/or
vitamin B6/B12 deﬁciencies due to deregulation of their normal
metabolism and/or low dietary intake.14e18 As an example, homo-
zygous genotypes with the C677T-MTHFR-polymorphism are 75%
less active, when a point mutation at nucleotide 677 causes the
replacement of cytosine with thymine. Insufﬁcient 5-MTHF
increases homocysteine because of inadequate re-methylation of
homocysteine into methionine.19 Indeed, Hcy, which is neurotoxic,
is metabolized by re-methylation by homocysteine methyl trans-
ferase, requiring 5-MTHF and vitamin B12. Another Hcy elimination
route is the trans-sulfuration pathway, where the conversion from
homocysteine to cysteine takes place in two enzymatic steps, each
of which involves vitamin B6 as a coenzyme.20
2.1.1. Folic acid intake during pregnancy
Folate needs increase substantially in pregnancy owing to the
enlargement of the uterus, the development of the placenta, and
the increasing red cell volume of the mother, as well as the growth
of the developing fetus. There is consistent scientiﬁc evidence that
folic acid is of critical importance both pre- and periconceptionally
in protecting the fetus fromneural tube defects (NTDs).21 Estimated
folate requirements increase by 50% to 600 mg/day during preg-
nancy, and even if the daily diet consists of food rich in folates, the
high requirement usually cannot be met through the consumption
of unfortiﬁed foods alone. For this reason, internationally, peri-
conceptional supplementation of 400 mg/day of folic acid is rec-
ommended for prevention of NTDs. Periconceptional
supplementation of 800 mg/day of folic acid combined with
multivitamins achieved a near 100% reduction of NTDs as well as
marked reductions of congenital heart defects.22e24 Daly et al.25
found that red cell folate levels higher than 906 nmol/L are asso-
ciated with maximal risk reduction of NTDs. In 1998 the German
Nutritional Survey evaluated folate concentrations in serum and in
red cells of women of childbearing age. Only 13% of the women
showed a red cell folate level higher than 906 nmol/L.26 With
a daily dosage of 800 mg folic acid, the preventive red blood cell
level of 906 nmol/L is reached within an average 4 weeks after the
start of supplementation27 (Fig. 2). In contrast, the current recom-
mendation to supplement 400 mg folic acid daily starting at least 4
weeks before conception is not enough to achieve optimal red cell
folate levels within 4 weeks; this requires at least 8e12 weeks of
daily intake.28 Though there might be an adaptation to increase
absorption of nutrients during pregnancy, optimal folate levels
have to be achieved around conception as the neural tube closes
between 23rd and 27th day of pregnancy. Thus, if one wishes to
maintain the current recommended supplementation period of 4
weeks before pregnancy, it may be preferable to increase the folic
acid dosage to 800 mg to achieve a maximal preventive effect
associated with a red cell folate level of greater than about
900 nmol/L. Maternal folic acid intake also correlates with birth-
weight,29 which may be explained through the role of folate in
nucleic acid synthesis. Moreover, associations between maternal
folate status and pathological changes in the placenta have been
Fig. 1. Overview of one-carbon metabolism. Modiﬁed from K. Pietrzik, I. Golly, D. Loew,
Handbuch Vitamine, Elsevier Urban & Fischer 2008.12 Folic acid is partly transformed
in the mucosa cell to dihydrofolate (DHF) and tetrahydrofolate (THF) and later in the
liver to 10-formyl-THF and 5,10-methylene-THF. Methylenetetrahydrofolate reductase
(MTHFR) catalyzes the transformation of 5,10-methylene-THF into 5-MTHF.13 Vitamin
B12 is essential for the conversion of 5-MTHF to 5,10-methylene-THF and, conse-
quently, for the methylation cycle and the biosynthesis of DNA and RNA.
Fig. 2. Change in red blood cell (RBC) folate concentration (nmol/L) of childbearing
women after a dosage of 800 mg (-) and of 400 mg (:) folic acid per day over a long
period of time. Placebo (C) was also considered. Blotted line indicates the lower RBC
folate level (906 nmol/L) required as an optimum risk reduction of neural tube defects
(NTDs). Modiﬁed from K. Pietrzik, I. Golly, D. Loew, Handbuch Vitamine, Elsevier Urban
& Fischer 2008.12
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reported (abruption placenta, infarct of the placenta), as well as
with spontaneous abortion. These associations are also evident for
homocysteine levels.30e33 Interestingly, an increased risk of NTDs
was associated with a high prevalence of a genetic variant in the
pathway of homocysteine metabolism causing HHCY.13,34 Results
from this study showed that the incidence of NTDs not only
correlates with the supply of folate but also that of vitamin B12.
Womenwith a low folate supply combined with low blood vitamin
B12 levels have a drastically increased risk of NTDs. Vitamin B12 is
involved in homocysteine metabolism being a coenzyme of the
methionine synthase and acting as a 5-MTHF methyl group donor
from methylcobalamine to homocysteine. Biochemically, vitamin
B12 and 5-MTHF are closely linked in regard to homocysteine re-
methylation. Thus, an increased tHcy level could be a causal factor
for NTD occurrence. These ﬁndings raise the potential that themost
effective periconceptional prophylaxis to prevent NTDs could be
the provision of both folic acid and vitamin B12. A meta-analysis of
randomized trials demonstrated that daily supplementation with
both 0.5e5.0 mg folic acid and 0.5 mg vitamin B12 can reduce blood
homocysteine concentrations by about a quarter to a third.35 In
particular, a folic acid dose of 800 mg was shown to have optimal
dosage with respect to lowering Hcy levels.36 It is possible that the
biological potential of folate might be even higher by using 5-MTHF
supplements, since signiﬁcantly higher red blood cell folate levels
were achieved by 5-MTHF in the form of calcium-L-methylfolate
compared to folic acid supplementation.28 Given that not only an
increased risk for NTDs37 but also various complications during
pregnancy such as abruptio placenta, placenta infarction and
spontaneous abortions are associated with MTHFR-poly-
morphism,38e40 provision of 5-MTHF might optimize the beneﬁts
of the folate supply.
2.1.2. Folic acid and public health measures
Even though the importance of periconceptional folic acid
supplementation for prevention of NTDs has been widely
acknowledged and supported by both scientiﬁc and governmental
recommendations throughout the world, its implementation is less
than satisfactory. Folate supplementation should be recommended
for all women who might become pregnant, and public health
measures should be taken to ensure that the diet of all womenwho
may bear children is enriched with an adequate amount of folic
acid. The current recommendation to supplement 400 mg of folic
acid at least 4 weeks before conception and in the ﬁrst trimester of
pregnancy should be re-assessed, particularly in areas where
a general food fortiﬁcation policy has not yet been implemented.
Currently, more than 50 countries worldwide have national regu-
lations for mandatory wheat-ﬂour fortiﬁcation with folic acid. In
response to fortiﬁcation there was a 26% risk decline of NTDs in the
US and approximately 46% in Canada with higher reductions in
high risk provinces (e.g. 78% in Newfoundland). Data from other
countries support the beneﬁt of those regulations. However, no
European country has yet developed national regulations for
mandatory folic acid fortiﬁcation. The discussion on fortiﬁcation
remains controversial because of concerns regarding potential risks
of chronic exposure to high-dose folic acid.41 The safety of very high
intakes of folic acid is really unknown, so the Institute of Medicine
recommends a tolerable upper intake level for folic acid of 1 mg/
day for adults.42 Speciﬁcally, high doses of folic acid are suggested
to mask anemia caused by vitamin B12 deﬁciency thus leading to
delayed diagnosis of neurological symptoms.43,44 Moreover, the
issue of folate and risk of cancer has received much public health
attention as a result of a potential dual role of folic acid in carci-
nogenesis. It seems that folic acid supplementation prevents the
development of tumors in normal tissues, whereas it accelerates
the development and progression of already growing neoplasms.41
The timing and the dose of folate intervention appears to be
responsible for this dual modulatory role of folate in carcinogen-
esis. However, evidence from randomized trials is lacking and
inconclusive, consequently further investigations are needed in this
ﬁeld.45 Similar discrepancies have been reported regarding the
adverse effects of folic acid on zinc absorption, as some authors
observed a signiﬁcantly decreased zinc absorption when pregnant
women received 350 mg/day iron-folic acid supplement for 2
weeks.46 Nevertheless, a 12-wk placebo-controlled trial failed to
detect any adverse effect of 400 mg/day folic acid supplementation
on zinc absorption.47
2.2. Antioxidants
Reactive oxygen species (ROS), reactive nitrogen species and
reactive chlorine species are synthesized in humans and animals
under physiological and pathological conditions.48 ROS oxidize
biomolecules such as DNA, lipids, proteins, leading to cell injury
and death. ROS are involved in female reproduction, in such
physiological processes as the endometrial cycle, luteolysis,
implantation, embryogenesis, and in pregnancy.49,50 An imbalance
in the equilibrium of pro-oxidants and antioxidants can result in
oxidative damage (OS), a key element in the pathogenesis of several
diseases.51 Antioxidants maintain homeostasis via effects on redox
status and/or redox-sensitive signaling pathways and gene
expression.52 By contributing directly and indirectly to antioxidant
defense, antioxidants enhance many aspects of the immune
response and limit pathological aspects of the cytokine-mediated
response.48 Many antioxidants are derived from the diet, such as
vitamin E and other tocopherols, vitamin C, b-carotene, whereas
proteins and peptides, such as glutathione (GSH), ceruloplasmin,
and metallothionein are synthesized endogenously.53,51 Other
micronutrients such as magnesium, copper, zinc, manganese and
selenium are involved in antioxidant defense as cofactors of
enzymes (i.e., coppereseleniumezinc in superoxide dismutase
(SOD), selenium in GSH peroxidase).48
The demands of normal pregnancy, especially during the third
trimester and at parturition, impose considerable systemic oxida-
tive, metabolic and inﬂammatory stress.54
2.2.1. Oxidative and inﬂammatory stress and the onset of
preeclampsia
Preeclampsia remains a frequent and potentially dangerous
complication of pregnancy, affecting 2e5% of pregnant women
worldwide, and it is a major cause of maternal death.55 As delivery
is the only known cure, and because it can occur from 20 weeks of
gestation onwards, preeclampsia can also lead to preterm delivery,
contributing to high neonatal mortality and morbidity. Thus,
preeclampsia is associated with both a maternal and a fetal
syndrome. The maternal syndrome of preeclampsia has previously
been ascribed to generalized maternal endothelial cell dysfunction.
However, the endothelial dysfunction is part of a more generalized
intravascular inﬂammatory reaction involving intravascular
leukocytes as well as the clotting and complement systems.54 In
preeclampsia both systemic oxidative stress and inﬂammatory
state are signiﬁcantly enhanced as part of the maternal syndrome.
The condition evolves in two stages (Fig. 3): stage 1 occurs without
symptoms in the ﬁrst half of pregnancy, due to poor placentation.
This causes an abnormally high pressure and pulsatile uteropla-
cental blood that induces oxidative stress and increased synthesis
and release of pro-inﬂammatory factors. During placentation,
trophoblast-cell invasion into the placental bed is inadequate, with
deﬁcient remodeling to enlarge the spiral arteries.56 The disturbed
pattern of blood ﬂow leads to reduced growth of the branches of
the placental villous tree, namely the narrow muscular arteries
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which perfuse lobules intermittently. Numerous studies suggest
that the “preeclamptic” oxidative stress arises from hypoxia/re-
perfusion.57 These include the demonstration of increased activity
of enzymatic pathways leading to superoxide generation, direct
measurement of free radical synthesis, activation of downstream
signaling pathways and evidence of enhanced lipid peroxidation.
Increased expression of stress response genes including heme
oxygenase 1 provides further support to this hypothesis. The
placenta appears to be the principal source of free radical synthesis
but maternal leukocytes and the maternal endothelium are also
likely contributors. Recent reports have suggested an important
role for placental trophoblast NAD(P)H oxidase in free radical
generation in preeclampsia.55,58 Stage 2 preeclampsia presents at
any time in the second half of pregnancy with the typical clinical
signs, and is characterized by systemic inﬂammatory stress.
Preeclampsia may be associated with fetal growth restriction,
because the damaged placenta has a reduced functional capacity.
Maternal health status and dietary factors may affect the
occurrence of preeclampsia. Chronic arterial and metabolic
diseases such as hypertension, obesity, type 2 diabetes and meta-
bolic syndrome are risk factors for preeclampsia. However, the
mechanisms by which obesity may cause gestational diabetes and
hypertensive disorders of pregnancy is still under investigation.59
Several possibilities include the adverse effects of insulin resis-
tance, elevated cholesterol and elevated leptin levels on blood
pressure. Moreover, in pregnancy the placenta is the primary
source of leptin.60 Remarkable increases in fetal and placental
leptin levels have been associated with preeclampsia. Leptin and
immune function are linked,61 and in particular leptin has a pro-
inﬂammatory role. Adipose tissue is a source of several other
inﬂammatory factors besides leptin (for example interleukins-1, -6
and tumor necrosis factor alpha), complement factors and
components of the coagulation/ﬁbrinolytic cascade. IL-6 stimulates
C-reactive protein synthesis which is positively correlated with
obesity, insulin resistance, elevated TNF-a and endothelial
dysfunction.62 Low grade systemic inﬂammatory activation is
typical of preeclampsia but the extent to which leptin, presumably
of placental origin, contributes is still not known. Diet may also be
relevant. Both excessive eating and consuming a poor quality diet
are associated with more systemic inﬂammatory stress. In the non-
pregnant state, meals and especially fat rich meals cause transient
inﬂammatory stress63,64 which may be sustained if the intervals
between meals are short.
2.2.2. Role of antioxidants in preeclampsia
Some nutrients may protect against preeclampsia. Calcium
supplementation has been reported to reduce the incidence of
preeclampsia, particularly in geographic regions with low calcium
intakes.65 Although the mechanism is obscure, supplements may
be assumed to increase chylomicron clearance after meals66 which
could reduce postprandial inﬂammatory stress.
Omega-3 long chain PUFA may also attenuate inﬂammatory
responses. However, the evidence from human studies is incon-
sistent if not conﬂicting.67 There is no conclusive evidence that
supplementation of omega-3 long chain PUFA would be beneﬁcial
for preventing preeclampsia68 and some data even suggest a risk
increasing effect.69
The antioxidant vitamin E is known to have multiple actions in
addition to preventing lipid peroxidation, including inhibition of
NAD(P)H oxidase activation and the inﬂammatory response.70
Given the abnormally low plasma vitamin C concentrations
reported in preeclampsia, a combination of vitamins C and E has
been postulated as a prophylactic strategy for prevention of
preeclampsia.71 However, there is no evidence that high doses of
vitamin C and vitamin E (1000 mg and 400 IU, respectively)
combined reduce the occurrence of preeclampsia.72 In particular,
some randomized controlled trials involving a large number of
pregnant women have shown a lack of beneﬁt in women receiving
antioxidants,73e76 as reported in Table 1. Therefore, the use of such
high-dose antioxidants cannot be justiﬁed in pregnancy.
Table 1
Characteristics and results from randomized controlled trials intervention studies indicating no effects on preeclampsia of high doses of vitamin C and Vitamin E (1000mg and
400 IU, respectively) combined.
Study design Result Reference
VIP Trial
Women identiﬁed as at increased risk of preeclampsia
from 25 hospitals (UK).
From the second trimester of pregnancy until delivery.
Vitamin group ¼ 1199; Placebo group ¼ 1205.
Risk Ratio (95% CI) ¼ 0.97 (0.80e1.17); p ¼ 0.754 70
Australian Collaborative Trial of Supplements (ACTS) study
Multicenter, randomized trial of nulliparous women between
14 and 22 weeks of gestation.
Vitamin group ¼ 935; Placebo group ¼ 942.
Risk Ratio (95% CI) ¼ 1.20 (0.82e1.75); p ¼ 0.57 71
WHO multicentre randomized trial
Pregnant women at high risk for preeclampsia in populations
of low nutritional status from India, South Africa, Peru and Vietnam.
Vitamin group ¼ 687; Placebo group ¼ 678
Risk Ratio (95% CI) ¼ 1.0 (0.9e1.3) 72
Multicenter, randomized, double-blind trial involving nulliparous
women at low risk for preeclampsia (USA).
Vitamin group ¼ 5088; Placebo group ¼ 5066.
Risk Ratioa (95% CI) ¼ 1.07 (0.91e1.25); p ¼ 0.42 73
a Severe pregnancy-associated hypertension alone or severe or mild hypertension with elevated liver-enzyme levels, thrombocytopenia, elevated serum creatinine levels,
eclamptic seizure, indicated preterm birth, fetal growth restriction, or perinatal death.
Fig. 3. Stages and factors involved in preeclampsia onset and development. ER:
Endoplasmic reticulum.
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These trial results add to the broader literature in cardiovascular
medicine where antioxidant supplements generally have no effect
on the progression of cardiovascular disease, despite good evidence
for an association of these disorders with biomarkers of oxidative
stress. Whether these trials suggest that oxidative stress is not part
of the pathogenesis of preeclampsia or the dose or the choice of
antioxidant prophylaxis is inappropriate, is unknown. The suscep-
tibility to oxidative stress of erythrocytes has been found to be
increased in preeclampsia as early as 14e20 weeks gestation prior
to onset of the clinical disease.77 This depended on glucose-6-
phosphate dehydrogenase (G6PD) activity, essential to maintain
intracellular NADPH activity, which was lower in preeclamptic
pregnancies compared to controls and unaffected by antioxidant
treatment with vitamins C and E. These ﬁndings provide the ﬁrst
evidence that decreased G6PD activity in preeclampsia causes
impaired redox regulation in erythrocytes and might explain why
antioxidant vitamin C/E supplementation in the VIP trial did not
protect from preeclampsia.77
Selenoenzymes play a critical role in regulating antioxidant
status, through the selenoproteins such as GSH peroxidases (GPx).
GPx removes the products of reactions with hydroperoxides and
oxidized lipoproteins, limiting adverse effects on the endothelium.
It is therefore of some interest that a poor maternal selenium (Se)
status may be a predictor of preeclampsia, given that women who
develop overt preeclampsia have a lower Se status.78 Vanderlelie
et al.79 studied the tissue levels of endogenous antioxidant proteins
(SOD, GHS peroxidase, thioredoxin reductase and thioredoxin) and
of lipid and protein oxidation in placental samples from normal and
preeclamptic pregnancies and found a decreased enzymatic anti-
oxidant capacity in placental tissue from preeclamptic women
compared to controls. Highly signiﬁcant reductions in serum Se
concentrations and plasma GSH peroxidase activity were found in
pregnancy per se compared to non-pregnant subjects.80 However,
even lower levels were found in preeclamptic mothers and their
babies. Subsequently, both preeclamptic mothers and their infants
had signiﬁcantly increased levels of oxidative stress-markers and
reduced placental GSH peroxidase activity. In rats, low Se intake
causes a preeclampsia-like syndrome81 which is consistent with
the human observations. Oxidative stress related to preeclampsia
might be a consequence of reduced antioxidant defense pathways
due to reduced Se availability. Reduced GPx may be related to
increased generation of toxic lipid peroxides contributing to the
endothelial dysfunction and hypertension of preeclampsia.
2.3. Vitamin A
Vitamin A is obtained from the diet either as pre-formed
vitamin A in the form of retinol or retinyl-esters, or as provitamin
A-carotenoids. The highest content of pre-formed vitamin A is
found in liver and liver oils of marine animals. Yellow and green
leafy vegetables provide signiﬁcant amounts of provitamin A-
carotenoids.82 However, high doses (<6 mg/day) of provitamin A
are needed to substitute pre-formed retinol.83 Retinol is the
endogenous metabolite and retinoic acid is the morphogenetically
active compound. Vitamin A plays a key role in ocular retinoid
metabolism and visual function as well as in cellular differentiation,
related to embryonic development in particular lung maturation
and immunity. Carotenoids exert antioxidant properties.
Fetal and neonatal vitamin A status depends on maternal
vitamin A status. Fetal/neonatal synthesis of retinol binding protein
is not sufﬁcient to ensure continuous supply from liver stores.
Hence, an adequate maternal vitamin A supply is essential to
ensure normal fetal growth and development.11 The Recommended
Daily Allowance (RDA), that is the amount of vitamin A that should
be taken to prevent vitamin deﬁciency, is about 0.8 mg/day.84 A
large heterogeneity, however, exists with recommended intakes
varying from 0.77 mg/day in UK85 to 1.1 mg/day in D-A-CH coun-
tries.86 Vitamin A deﬁciency during pregnancy seems to be asso-
ciated with preterm birth, LBW and low neonatal liver stores.87e90
Low vitamin A status of the newborn appears to contribute to the
risk for bronchopulmonary dysplasia (chronic lung disease). Low
neonatal liver stores and a low supply during lactation also appear
to increase the risk for infection.90
The German Nutrition Society (DGE) recommends a 40%
increase in vitamin A intake for pregnant women and a 90%
increase for breastfeeding women. The American Academy of
Pediatrics Committee on Nutrition (1998)91 cites vitamin A as one
of the most critical vitamins during pregnancy and the breast-
feeding period, especially in terms of lung function andmaturation.
If the mother has suboptimal intake, her supply to fetus will be
inadequate, as will later the vitamin A content of her milk. These
inadequacies cannot be rectiﬁed by postnatal supplementation. A
clinical study in pregnant women with short birth intervals or
multiple births showed that almost 1/3 of the women showed
plasma retinol levels below 1.4 mmol/L which can be taken as
borderline deﬁciency.92 Despite the fact that vitamin A and beta-
carotene rich food is generally available, risk groups for low
vitamin A supply exist in the western world.
Even though 25% of the population have an inadequate retinol
supply93 pregnant women are routinely advised against
consumption of liver, the major dietary source of pre-formed
vitamin A. This advice is based on two main considerations. The
ﬁrst is that there is no doubt that synthetic retinoids, used for the
treatment of severe acne are teratogenic.94 Secondly there are case
reports of teratogenicity associated with high-dose supplementa-
tion with, or overdose of, vitamin A. This raises the question which
source of vitamin A supply in pregnancy and lactation can be
considered adequate and safe. Alternative strategies to augment
maternal vitamin A status are either selective supplementation
with retinol, or supplementation/fortiﬁcation with isolated b-
carotene. However, the conversion of b-carotene to retinol may be
limited and varies with genetic polymorphisms frequently found in
the population.95 Excessive dietary intake has been associated with
teratogenicity in humans in 20 reports published until 1986, and no
further reports since that time.94 However, there is a lack of
adequate data on a teratogenic effect of pre-formed vitamin A
(retinol or retinylester).96 In particular there are no data showing
any relationship between consumption of liver and malformations.
Nevertheless, a daily intake of more than 3 mg pre-formed Vitamin
A (10,000 IU) should be avoided by women who are or who might
become pregnant based on a precautionary principle.11 During the
ﬁrst trimester of pregnancy vitamin A intake from liver or
supplements is not recommended. However, especially during the
third trimester, sufﬁcient vitamin A intake that is 100e150% RDA is
strongly recommended to ensure sufﬁcient neonatal liver and lung
stores of vitamin A for adequate tissue maturation.1
2.4. Vitamin D
Over the past decade observational studies in non-pregnant
individuals have associated low 25-OH-vitamin D levels in plasma
with an increased risk of various common chronic diseases such as
colon, breast and prostate cancer, metabolic syndrome, hyperten-
sion, multiple sclerosis, type I diabetes, and inﬂammatory bowel
disease, even though causality has not been ﬁrmly established.97 In
addition to its action on calcium metabolism and bone homeo-
stasis, there are other physiologic systems in which vitamin D, the
steroid hormone, 1,25-dihydroxyvitamin D (1,25[OH]2D), and its
receptor generate biological responses.98 For example, 1,25[OH]2D
inhibits parathyroid hormone (PTH) secretion but promotes insulin
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secretion, it inhibits adaptive immunity but promotes innate
immunity. So vitamin D appears to exert anti-inﬂammatory and
anti-microbial activity through the innate immune system and to
inhibit cell proliferation while stimulating cell differentiation.99
Estimates of the prevalence of vitamin D deﬁciency or insufﬁ-
ciency vary greatly depending on the chosen cut-offs for serum 25-
hydroxyvitamin D (25[OH]D) concentrations.100,101 Indeed, the
threshold for optimal 25[OH]D concentration could vary with
regards to the expected effects, whichmay relate to bone health but
also to the non-classical actions of vitamin D on maternal and fetal
outcomes. In Australia and New Zealand currently a dietary vitamin
D intake for pregnant women of 200 IU/day has been recom-
mended102,103 while 400 IU/day are recommended in the United
Kingdom104 and 600 IU/day in the United States and Canada.105
Basing adequate intake allowances of vitamin D on vitamin D’s
actions on calcium and bone tissues is the subject of widespread
controversy.106,107 Given the evolving concept of vitamin D-sufﬁ-
ciency, it is currently considered that sufﬁciency may be deﬁned by
a serum 25[OH]D levels >75 nmol/L.100 By this criterion, the
prevalence of vitamin D insufﬁciency during pregnancy could be as
high as 70% in western countries.108 The related potential public
health implications warrant attention.
Recent surveys conﬁrm that 25[OH]D concentrations in preg-
nant women are not different from those of non-pregnant women
and are signiﬁcantly associated with ethnicity.109,110 Vitamin D
deﬁciency is more common in dark-skinned individuals living in
northern countries where sunlight is less effective in producing
vitamin D3 (1,25[OH]2D) in darker skin because the ultraviolet light
is absorbed by the skin pigment. In addition, low sunlight exposure,
the habit of covering the skin, and a diet low in vitamin D and
calcium may all contribute to lower vitamin D concentrations in
non-Western immigrants to northern countries.111,112 A study in
pregnant women of several ethnic backgrounds living in The Hague
(the Netherlands) showed that mean serum 25[OH]D concentra-
tions were signiﬁcantly lower in women of Turkish, Moroccan, and
other non-Western groups than those in Western women.110 A
comparison of the observed serum 25[OH]D concentrations in the
population of the USA measured in the NHANES III (1988e1994)
and NHANES 2000e2004 studies suggests an overall decline in
vitamin D status over the past 10e15 y.109
Vitamin D status may be critical with regards to pregnancy and
fetal/infant outcomes.113 Severe vitamin D deﬁciency causes
modest hypocalcemia and secondary hyperparathyroidism and
osteomalacia in non-pregnant adults, but no reports have docu-
mented worsening during pregnancy.114 Despite the signiﬁcantly
higher needs of calcium to be passed on to the developing fetus,
maternal adaptations provide the necessary calcium relatively
independent of vitamin D status. Table 2 presents observational
studies addressing the association between poor pregnancy
outcomes and vitamin D.115e120 Vitamin D deﬁciency seems to be
associated with an increased risk of preeclampsia. The pathogen-
esis of preeclampsia involves several biological/molecular path-
ways that may be affected by vitamin D, including placental
dysfunction/insufﬁciency, abnormal angiogenesis, excessive
inﬂammation, and hypertension.121e124 However, a recent study
showed no association between vitamin D deﬁciency and
preeclampsia125 to suggest that low serum vitamin D levels in
preeclampsia do not necessarily indicate dietary deﬁciencies but
may be a consequence of placental dysfunction or a secondary
consequence of systemic inﬂammation. The placenta synthesizes
active 1,25[OH]2D from its precursor.125e127
A possible role of vitamin D in maintaining normal glucose
homeostasis is discussed in the review by Peechakara et al.128 In
both animal and human studies, vitamin D depletion appears to be
associated with insulin resistance and impaired insulin secre-
tion.129 In particular, a signiﬁcant and strong association between
Table 2
Studies examining the association between vitamin D status and diabetes or preeclampsia.
Outcome Study Design Result Reference
Vitamin D deﬁciency
and preeclampsia
Case-control study of pregnant women followed
from less than 16 wk gestation to delivery.
Nulliparous pregnant women who developed
preeclampsia (n ¼ 55) or did not develop
preeclampsia (n ¼ 219)
Adjusted serum 25[OH]D concentrations in early
pregnancy 15% lower in women who subsequently
developed preeclampsia compared with controls.
Adjusted odds ratio (95% CI) ¼ 2.4 (1.1e5.4)
115
Longitudinal study included 170 healthy
normotensive pregnant women. During the study,
160 women remained NT and 10 developed
preeclampsia at the third gestational period
Circulating levels of 1,25-[OH]2D not altered in
women before they developed preeclampsia.
116
Thirty-two patients with preeclampsia and 20
normotensive women with singleton gestations
in the third trimester.
Increased bone resorption and decreased bone
formation occur in preeclampsia in both mother
and fetus.
Normal pregnancy: maternal coupling index (CI)
of markers of bone turnover ¼ þ3.28; fetal CI ¼ þ11.8.
Mild preeclampsia: maternal CI ¼ þ1.4; fetal CI ¼ 30.85.
Severe preeclampsia: maternal CI ¼ 25.71; fetal
CI ¼ 70.02
117
Vitamin D deﬁciency
and insulin resistance
Nested case-control study among a prospective
cohort of 953 pregnant women (Omega Study).
Incident GDM cases (n ¼ 57) and women who
were not diagnosed with GDM (n ¼ 114)
Each 5 ng/ml decrease in 25[OH]D concentrations
was related to a 1.29-fold increase in GDM risk.
Odds ratio (95% CI) ¼ 1.29 (1.05e1.6)
118
Prospective study a convenience sample of 307
pregnant women.
Signiﬁcant linear associations were therefore found
between log-transformed 25[OH]D and fasting
glucose, fasting insulin and HOMA-insulin resistance
119
Cross-sectional study was conducted on 741 pregnant
women with no previous history of diabetes mellitus
Prevalence of severe vitamin D deﬁciency in GDM
patients higher than in normoglycaemic pregnancies.
25[OH] D levels: GDM pregnancies
¼ (16.49  10.44) vs normal pregnancy
¼ (22.97  18.25); p ¼ 0.009.
Strong correlation between the HOMA index
and serum levels of vitamin D.
120
GDM: gestational diabetes mellitus.
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vitamin D deﬁciency and b-cell dysfunction has been reported in
126 healthy, glucose-tolerant subjects.130 Moreover, some studies
have found a signiﬁcant association between maternal plasma 25
[OH]D concentrations in early pregnancy and the risk for gesta-
tional diabetes mellitus (GDM), fasting glucose levels or the
Homeostasis Model Assessment (HOMA) index118e120 (Table 2).
2.4.1. Fetal and infant outcomes
Maternal vitamin D deﬁciency predisposes newborns to
neonatal hypocalcaemia, and to later rickets. Observational studies
also suggest that the bone mass of the newborn is related to the
vitamin D status of the mother (reviewed by Salle et al.131). In
a longitudinal study, it has been reported that children at 9.5 years
of age born to vitamin D-deﬁcient (serum 25[OH]D concentration
<50 nmol/L) mothers (n ¼ 379) had signiﬁcantly smaller arm-
muscle area in comparison with children born to mothers
without deﬁciency (n ¼ 189).132 Moreover, several studies propose
low vitamin D concentrations during prenatal or early life devel-
opment as a cause of a greater risk of later development of multiple
sclerosis, cancer, insulin dependent diabetes mellitus, and schizo-
phrenia.114 There is growing evidence that in rodents vitamin D
deﬁciency during pregnancy may disrupt fetal brain development
and may lead to persistent changes in the adult brain.133 The
absence of vitamin D during fetal development on protein
expression in the adult brain was studied in pregnant female rats
kept vitamin D-deﬁcient until birth.97 At week 10, protein expres-
sion in the progeny’s prefrontal cortex and hippocampus was
compared with control animals. Developmental vitamin D deﬁ-
ciency caused a dysregulation of 36 brain proteins involved in
several biological pathways including oxidative phosphorylation,
redox balance, cytoskeleton maintenance, calcium homeostasis,
chaperoning, PTMs, synaptic plasticity and neurotransmission. A
computational analysis of data revealed that nearly half of the
deregulatedmolecules have also been shown to be misexpressed in
either schizophrenia and/or multiple sclerosis. Moreover, in rats
a clinical phenotype was induced characterized by hyper-
locomotion in the offspring at adult age.134 A recent meta-analysis
shows that the risk of type 1 diabetes is signiﬁcantly reduced in
infants whowere supplemented with vitamin D compared to those
who were not supplemented suggesting that Vitamin D supple-
mentation in early childhood may offer protection against the
development of type 1 diabetes.135 During pregnancy, few obser-
vational studies suggest that vitamin D insufﬁciency is associated
with childhood incidence of type 1 diabetes [adjusted odds ratio
(95% CI): 0.74 (0.56, 0.99)].136 There are also arguments that low
maternal vitamin D intake may be associated with the risk of
recurrent wheeze at 3 or 5 years which suggests that childhood
asthmamay be inﬂuenced bymaternal diet during pregnancy.137,138
For an example, mothers consuming high daily intakes (median:
724 IU) during pregnancy had a lower risk of having a child with
recurrent wheeze at 3 years of age [odds ratio (95% CI): 0.39 (0.25,
0.62), p < 001] with respect to mothers in the lowest quintile of
daily intakes (356 IU).137 On the whole, the available data suggest
that vitamin D status during pregnancy is not only linked to
maternal skeletal health and fetal skeletal formation but also may
affect maternal outcomes and longer term health of the child,139
and that the high risk of developing diseases characterized by
systemic inﬂammation may be attributable to vitamin D anti-
inﬂammatory properties.99 However, there are too few relevant
studies to form a strong evidence base, mostly because of small
sample size, and because the majority are observational. Further
evidence from appropriately designed interventional trials is
required. Additional studies are also needed to determine optimal
25[OH]D concentrations with regards not only to bone health but
also to non-classical actions of vitamin D on maternal and fetal
outcomes. Vitamin D-deﬁcient or insufﬁcient neonates are at risk of
hypocalcaemia and rickets, and recommendations to support an
adequate 25[OH]D status of women during pregnancy might thus
be best directed toward ensuring vitamin D-sufﬁciency in the
newborn. Unfortunately, there is a lack of consensus on the
thresholds of maternal and neonatal plasma 25[OH]D that deﬁne
the lower limit of adequacy or sufﬁciency, and international dietary
recommendations for dietary vitamin D intake vary considerably.
Considering the contrasting opinions on increasing of vitamin D
intake recommendations140 and the limited data on the biological
effects, monitoring of effects with higher intakes of vitamin D
should be promoted.
2.5. Iron
Neonates at term birth have a total body store of about 270 mg
of iron, all derived from the mother. Some of this iron is made
available from the stopping of menses, and some from increased
absorption during pregnancy. The mother will however have to
provide about 400mg fromher own hepatic stores. Moreover, extra
iron is required for the formation of the placenta, as well as to
expand maternal red cell mass and cope with blood loss during
delivery.141 Women often become pregnant without adequate iron
reserves or are already iron deﬁcient. The most severe consequence
of iron depletion is maternal iron deﬁciency anemia (IDA). IDA may
be aggravated during pregnancy owing to fetal demands for iron.142
Iron status seems to be implicated in some pregnancy disorders
affecting mother and fetus, such as preeclampsia, prematurity and
premature rupture of membranes.143,144 In a prospective study of
1650 pregnancies, low iron status early in pregnancy was found to
be inversely related to placental size.145 Either anemia in the per-
iconceptional period may have an independent effect on infant
growth by inﬂuencing hormone synthesis,146 or the moderate
preconceptional anemia may turn to a more severe anemia during
pregnancy142 leading to the observed growth deﬁcits. Animal
studies suggest that maternal IDA may be a predictor for increased
disease risk in later life,147 and recently it has been hypothesized
that maternal iron status might be involved in cognitive develop-
ment of the infant.148 Some studies showed that maternal IDA is
linked to altered infant behavioral and neural development, and
suggested to result in irreversible effects on neurochemistry and
neurobiology due to altered myelination of white matter, changes
in monoamine metabolism in striatum and functioning of the
hippocampus.149e151
2.5.1. Iron supplementation
An adequate iron intake is mandatory for normal fetal growth
and development. Nevertheless, an unresolved question is whether
prophylactic iron supplementation does reduce the rates of preg-
nancy complications,152 or whether anemia affects placental
development solely during early pregnancy and therefore would
prevent complications by supplementation prior to pregnancy.
Routine iron supplementation is still common during pregnancy
but potentially harmful effects in iron sufﬁcient women are
debated. In general, randomized controlled trials showed that
prophylactic iron supplementation during early pregnancy (i.e.,
30e40 mg/day taken from the 20th week of gestation until
delivery) can increase hemoglobin concentrations and body iron
stores in pregnant women.153e156 Nevertheless, results related to
clinical endpoints are conﬂicting. Some authors reported that
supplementation increased birthweight and reduced the incidence
of preterm delivery,152,157 whereas others found no effect155,158 or
negative effects on clinical endpoints, possibly due to untoward
effects of iron overload in non-anemic mothers.133 In this context,
Ziaei and colleagues149 concluded that routine iron
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supplementation (50 mg) in non-anemic women was not rational
and might be harmful. Their randomized controlled trial evidenced
that small-for-gestational-age (SGA) birth rate and the number of
women with hypertension disorders increased signiﬁcantly in the
intervention in comparison with the control group, being 15.7% vs
10.3%, p ¼ 0.035, and 2.7% vs 8%, p ¼ 0.05, respectively. The dosage
of iron is a critical issue in relation to potential side effects. In
excess, iron may be toxic because of its ability to generate reactive
oxygen species and to induce cell and tissue damage.159 During
pregnancy, increased numbers of mitochondria lead to increased
synthesis of unpaired electrons and therefore may contribute to
oxidative stress, with a peak vulnerability during the second half of
pregnancy for fetal health and gestational outcomes.160 A recent
observation study reported a 2-fold higher prevalence of GDM,
hypertension, and metabolic syndrome in mid-pregnancy among
iron-supplement users,161 suggesting that iron excess should be
avoided.160
However, iron deﬁciency anemia should certainly be prevented
and treated. Selective prophylaxis seems to be the most effective
and appropriate approach: screening of ferritin levels in early
pregnancy may identify women who may beneﬁt from iron
supplementation.
Ongoing studies are evaluating the effect of different timing of
iron supply in pregnancy (i.e. early or late pregnancy) as well as the
different frequency of supplementation (i.e., daily or weekly).
Moreover, different forms of iron supplements are of interest given
that iron status is inﬂuenced both by the iron content and the
bioavailability of iron: indeed heme iron from animal foods is better
absorbed than non-heme iron from vegetables. Similarly FeEDTA
and liposome embedded/encapsulated forms may have a higher
bioavailability than ferrous fumarate or FeSO4.162e164 Polymeric
forms may have advantages because of a lesser likelihood to be
reactive. The further exploration of different strategies could
inform future practice recommendations.
2.6. Iodine
Approximately half of the European population is still suffering
from an inadequate iodine supply. Low urinary iodine excretion is
especially common among pregnant women and school children.
Table 3
Micronutrient dietary sources, dietary reference intakes for pregnant women, unresolved issues and proposal of priority for future research in pregnancy.
Micronutrient Dietary source Dietary Reference
Intakes (DRIs)
Issues
To be re-assessed Priority for future research
Folate (DEF)
(mg/day)
Enriched cereal grains, dark leafy
vegetables, enriched and whole-grain
breads and bread products, fortiﬁed
ready-to-eat cereals
600 (FAO/
WHO)11;
600 (IOM)84;
300
(COMA, UK)85;
600 (D-A-CH)86;
600
(Australia)103;
500 (NNR)177
400a from 4 wks before until
12 wks after conception21
Dose/timing combination: 400 starting
8e12 wks before pregnancy or 800
starting 4 wks before pregnancy.
Investigation on toxicity of chronic
high doses
Vitamin A (retinol
equivalent)
(mg/day)
Liver, dairy products, ﬁsh, darkly
colored fruits, leafy vegetables
0.8 (FAO/
WHO)11;
0.77b (IOM)84;
0.7 (COMA,
UK)85;
1.1 (D-A-CH)86;
0.8 (Australia)103
To avoid intake
of vitamin A rich liver
and liver foods during
pregnancy
To investigate effects of higher intakes
of vitamin A during the 3rd trimester
of gestation
Vitamin D
(mg/day)
Fish liver oils, ﬂesh of fatty ﬁsh, liver,
eggs, fortiﬁed milk products, fortiﬁed
cereals
5 (FAO/WHO)11;
10 (UK)104;
15 (IOM)105;
5 (D-A-CH)86
5 (Australia)103
Optimal dose of Vitamin D
to achieve sufﬁciency.
To determine optimal 25[OH]D concentrations
with regards to bone health and non-classical
actions of vitamin D on maternal and fetal
outcomes.
Need of selecting high risk population for
routine supplementation during/before
pregnancy.
Iron (mg/day) Fruits, vegetables, fortiﬁed bread and
grain products such as cereal (nonheme
iron), meat and poultry (heme iron)
27 (IOM)84;
14.8
(COMA, UK)85;
30 (D-A-CH)86;
27 (Australia)103
Routine iron supplementation Selective prophylactic supplementation.
To avoid overload.
To evaluate the effects of timing and
frequency of supplementation, and to
investigate the bioavailability of different
forms of supplements
Iodine (mg/day) Marine origin, processed foods,
iodized salt
220 (IOM)84;
140
(COMA, UK)85;
230 (D-A-CH)86;
220
(Australia)103;
200e250
(WHO)166;
175 (NNR)177
Supplementation of 100
e150 mg Iodine in countries
with a mean iodine uptake
below 150 mg/day
To control urinary iodine (UI) excretion by
epidemiological studies under the current
push to reduce salt intake in
the general population
ANTIOXIDANTS
Selenium
(mg/day)
(including
selenoproteins)
Bread and cereals, meat, milk/dairy178 28 (2nd
trimester) e 30
(3rd trimester)
(FAO/WHO)11;
60 (IOM)84;
60 (COMA, UK)85;
65 (Australia)103;
55 (NNR)177
Circumstantial evidence that
selenium supplements may
prevent preeclampsia
To investigate other more speciﬁcally
targeted antioxidant strategies for
prevention of preeclampsia including
an RCT of selenium supplementation in
low selenium populations
a DEF ¼ Dietary Folate Equivalents.
b RAE ¼ Retinol Activity Equivalent.
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During pregnancy the demand for iodine is substantially higher
than in non-pregnant women increasing from at least 100 mg/day to
about 200e250 mg/day to maintain free thyroxine (fT4) during
pregnancy within the normal range. This is because of the
increased demand for thyroxine during the ﬁrst trimester, the
increase in thyroxine-binding protein and the higher loss of iodine
in the urine.165 TheWHO recommendation for iodine intake during
pregnancy and lactation has recently increased from 200 to 250 mg/
day and suggested that amedian urinary iodine concentration (UIC)
of 150e250 mg/L indicates adequate iodine intake.166 WHO
recommends iodine supplementation in pregnancy only in coun-
tries where less than 90% of households use iodized salt or where
the median UIC in school children is below 100 mg/L. However, the
use of iodized salt in households might be not enough to cope with
the increased iodine demand during pregnancy and therefore the
American Thyroid Association recommends an iodine supplemen-
tation of 150 mg/day in pregnant women.167
Low iodine intake in pregnancy is associated with a higher
incidence of miscarriage, SGA infants, and a delay in mental
development or even permanent mental retardation, reduced
intellectual ability and hearing loss.166 Thyroxine is necessary for
normal brain development168 and therefore a sufﬁcient iodine
intake especially within the ﬁrst trimester is important.169 Even
mild iodine deﬁciency and subclinical hypothyroidism may affect
fetal growth. Pregnant women with UICs during the 3rd trimester
below 50 mg/L were signiﬁcantly more likely to have a SGA infant,
and mean birthweight was lower, than among women with the
UICs between 100 and 149 mg/L [adjusted odd ratio (95%CI): 0.15
(0.03e0.76)]. Higher TSH levels were also associated with a higher
risk of having an SGA baby or a LBW newborn.170 The later mean
intelligence quotient of children born to women an UIC below
50 mg/L was found signiﬁcantly lower compared to controls with
adequate iodine supplementation.171 Recent cross-sectional studies
in European countries and the USA show a median UIC in pregnant
women in the range of 95e130 mg/L.166,172
Excessive iodine intake like in Japan did not affect either the
maternal or the off-spring thyroid function.173 Other studies show
an increase in iodine-induced hyperthyroidism in areas with
previously low iodine intake and also a higher prevalence of
autoimmune thyroiditis (AIT) is discussed.166 Therefore, it has been
suggested to test the thyroid function of women who plan a preg-
nancy in geographical areas with known iodine deﬁciency, but this
concept is controversial.174
During the 1st trimester the fetus depends on the thyroxine
supplied by the mother, and thereafter mainly on maternal iodine
intake. Thematernal fT4 concentration therefore is more important
for fetal brain development than TSH, although elevated TSH may
indicate a deﬁcient thyroid reserve of the mother and AIT should
then be excluded.168,172 If AIT is conﬁrmed, L-Thyroxin supple-
mentation is indicated to keep TSH and fT4 within the low normal
range. After the 12th week of gestation, iodine should be added in
a dosage of 150 mg/day. If AIT is excluded, only iodide supplemen-
tation (150e200 mg/day) is recommended throughout pregnancy
and lactation in several countries with frequent occurrence of
iodine deﬁciency (e.g. Germany), but obviously the iodine dose
supplied to prevent and treat iodine-deﬁciency disorders should be
at a safe level. If iodine status is good (median UIC, 200e299 mg/L)
or excessive (median UIC, >300 mg/L) additional supplementation
should be avoided. Iodized salt should be provided only in regions
where iodine intake is insufﬁcient according to the WHO
recommendations.
The thyroid is the organ with the body’s highest selenium
content. Combined iodine and selenium deﬁciency is the cause of
myxoedematous cretinism. This is because selenium-dependent
enzymes (GPx’s) are important to prevent the thyroid from
oxidative damage.175 Sufﬁcient dietary iodine and selenium intakes
are necessary for normal thyroid function and low selenium intake
might initiate or exacerbate AIT. Selenium supplementation in
countries with low selenium intake might attenuate the inﬂam-
matory activity within the thyroid in patients suffering from AIT.
Supplementation of 200 mg selenium per day during pregnancy and
9 months after delivery in women suffering from AIT was reported
to prevent the post-partum exacerbation of AIT and decreasing the
incidence of post-partum hypothyroidism.176 This study, however,
needs conﬁrmation especially in countries with sufﬁcient selenium
intake.
3. Conclusions
In addition to their classical essential roles, current evidence
seems to suggest that vitamins and minerals have added bio-
functionality which may be particularly important in pregnancy. In
particular, besides meeting desirable intakes, the balance between
antioxidants and pro-oxidants needs to be sustained. For example
supplementation with iron should not be excessive in order to
avoid adverse outcomes. Moreover, synergisms between different
micronutrients may enhance their biological potential, for example,
the combination of folic acid and vitamin B12 appears to further
reduce the risk of occurrence of NTDs.
In this context, more information on the biological mechanisms
underpinning relationships between micronutrients and preg-
nancy outcomes is needed Moreover, discrepancy between results
from observational studies and randomized controlled studies
often exists (i.e., role of folic acid in carcinogenesis), and data from
trials are often conﬂicting as well, as suggested for example by the
disagreement on the need for iron prophylaxis or on the harmful
amount and timing of vitamin A intake (Table 3). Similarly, large
trials evidenced no effect of the prophylactic use of high doses of
vitamin C and vitamin E combined on the prevention of
preeclampsia. Moreover, it should be investigated whether the
strategy of increasing folic acid dose from 400 to 800 mg/daymay be
applicable to pregnancy state where adaptation happens to
increase absorption of nutrients. Vitamin D insufﬁciency is
increasingly common amongst pregnant women and the conse-
quences may extend beyond the recognized inﬂuence of neonatal
calcium deﬁciency and rickets. The proposed relationships between
hypovitaminosis and gestational diabetes, and with preeclampsia,
require further investigation, as does the inﬂuence of maternal
supplements required to achieve sufﬁciency. Adequately powered,
randomized controlled trials with long periods of follow-up are
needed to establish causality and the best formulation, dose,
duration and period of supplementation during pregnancy. The
inﬂuence on the health of the child in later life should routinely be
considered. Clearly, further studies are needed to determine the
optimal 25[OH]D concentrations with regards not only to bone
health but also to non-classic actions of vitamin D on maternal and
fetal outcomes. The beneﬁt of iodine for the brain development of
the offspring during pregnancy is well established. Themain source
of iodine is the use of iodized salt in household and food industry.
The current recommendations to reduce salt intake to prevent
hypertension might inﬂuence iodine uptake of women in child-
bearing age and therefore especially also in developed countries
surveys of iodine intake is recommended and increase of the
amount of iodine in fortiﬁed salt has to be considered.
Micronutrient deﬁciencies can undoubtedly have profound
inﬂuences on the health of the mother and her child, but they
remain areas of uncertainty and controversy which hinder the
development of robust public health guidance, Many of these,
addressed in the review, would be clariﬁed by well conducted
randomized controlled clinical trials including childhood follow-
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up. These are an essential pre-requisite to inform evidence based
policy decisions and recommendations for clinical practice.
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